ATTR-CM Educational Toolkit
The 木瓜直播 is leading a national effort to improve the recognition, diagnosis, and management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM). In collaboration with clinicians, scientists, and patient advocates, this initiative seeks to reduce diagnostic delays, strengthen multidisciplinary care, and expand awareness of emerging therapies, including gene-based approaches to cardiovascular disease.
This educational toolkit supports both healthcare professionals and patients/caregivers in navigating the complexities of ATTR-CM. The resources are designed to promote disease awareness and education, early recognition, informed decision-making, and meaningful conversations about clinical trial participation. An accompanying clinician guide equips providers to initiate and support discussions around gene therapy and evolving treatment pathways.
Toolkit & Resources Coming July 2025!
Educational materials for healthcare professionals and patients/caregivers will be available here in July 2025.
Stay tuned for updates and access to downloadable guides, patient education materials, and clinician-focused resources.
| Intellia Therapeutics is proud to support the 木瓜直播’s ATTR-CM Awareness and Education. |  |
Disclaimer: The materials are for educational purposes only. The content provided does not constitute an endorsement or instruction by the 木瓜直播 or the American Stroke Association.